173 related articles for article (PubMed ID: 15653117)
1. Effects of xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable angina.
Li JJ; Hu SS; Fang CH; Hui RT; Miao LF; Yang YJ; Gao RL
Clin Chim Acta; 2005 Feb; 352(1-2):217-24. PubMed ID: 15653117
[TBL] [Abstract][Full Text] [Related]
2. Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X.
Li JJ; Wang Y; Nie SP; Li Q; Li YS; Huang Y; Hui RT
Int J Cardiol; 2007 Oct; 122(1):82-4. PubMed ID: 17196275
[TBL] [Abstract][Full Text] [Related]
3. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease.
Zhao SP; Liu L; Cheng YC; Shishehbor MH; Liu MH; Peng DQ; Li YL
Circulation; 2004 Aug; 110(8):915-20. PubMed ID: 15313947
[TBL] [Abstract][Full Text] [Related]
4. Time course of rapid C-reactive protein reduction by pravastatin in patients with stable angina.
Li JJ; Fang CH; Qian HY; Hu WL
Angiology; 2006; 57(1):1-7. PubMed ID: 16444450
[TBL] [Abstract][Full Text] [Related]
5. Effects of withdrawal of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with coronary artery disease.
Hu CL; Li YB; Tang YH; Chen JB; Liu J; Tang QZ; Zhang QH; Huang CX
Cardiovasc Drugs Ther; 2006 Jun; 20(3):185-91. PubMed ID: 16775668
[TBL] [Abstract][Full Text] [Related]
6. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
[TBL] [Abstract][Full Text] [Related]
7. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Dornbrook-Lavender KA; Joy MS; Denu-Ciocca CJ; Chin H; Hogan SL; Pieper JA
Pharmacotherapy; 2005 Mar; 25(3):335-44. PubMed ID: 15843280
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
9. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction.
Lu Z; Kou W; Du B; Wu Y; Zhao S; Brusco OA; Morgan JM; Capuzzi DM; ; Li S
Am J Cardiol; 2008 Jun; 101(12):1689-93. PubMed ID: 18549841
[TBL] [Abstract][Full Text] [Related]
10. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
11. Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids.
Shinn AH; Carr-Lopez SM; Smith JW; Elledge EA; Smith TJ
Curr Med Res Opin; 2005 Feb; 21(2):207-14. PubMed ID: 15801991
[TBL] [Abstract][Full Text] [Related]
12. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
13. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
Bays HE; Davidson M; Jones MR; Abby SL
Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
[TBL] [Abstract][Full Text] [Related]
14. Potential protective effect of long-term therapy with Xuezhikang on left ventricular diastolic function in patients with essential hypertension.
Ye P; Wu CE; Sheng L; Li H
J Altern Complement Med; 2009 Jul; 15(7):719-25. PubMed ID: 19552598
[TBL] [Abstract][Full Text] [Related]
15. Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Bayés B; Granada ML; Lauzurica R; Pastor MC; Navarro M; Bonet J; Llopis MA; Romero R
Transplant Proc; 2005 Nov; 37(9):3808-12. PubMed ID: 16386546
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
Bays H; Rhyne J; Abby S; Lai YL; Jones M
Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
[TBL] [Abstract][Full Text] [Related]
18. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
19. Association between inflammation, lipid and hemostatic factors in patients with stable angina.
Sagastagoitia JD; Sáez Y; Vacas M; Narváez I; Sáez de Lafuente JP; Molinero E; Magro A; Lafita M; Santos M; Escobar A; Iriarte JA
Thromb Res; 2007; 120(1):53-9. PubMed ID: 16916537
[TBL] [Abstract][Full Text] [Related]
20. Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction?
Gianturco V; Bellomo A; D'Ottavio E; Formosa V; Iori A; Mancinella M; Troisi G; Marigliano V
Arch Gerontol Geriatr; 2009; 49 Suppl 1():129-33. PubMed ID: 19836626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
